Crossmark

Efficacy and safety of alirocumab 150 mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON

Crossref DOI link: https://doi.org/10.1016/j.jjcc.2018.10.004

Published Print: 2019-03

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Teramoto, Tamio

Kiyosue, Arihiro

Ishigaki, Yasushi

Harada-Shiba, Mariko

Kawabata, Yumiko

Ozaki, Asuka

Baccara-Dinet, Marie T.

Sata, Masataka
Funding

Funding for this research was provided by:

Regeneron Pharmaceuticals

Sanofi
License Information

Text and Data Mining valid from 2019-03-01

Text and Data Mining valid from 2019-03-01

Version of Record valid from 2018-11-21
More Information

This article is maintained by: Elsevier

Article Title: Efficacy and safety of alirocumab 150mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON

Journal Title: Journal of Cardiology

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.jjcc.2018.10.004

Content Type: article

Copyright: © 2018 The Authors. Published by Elsevier Ltd on behalf of Japanese College of Cardiology.

Document is current

Any future updates will be listed below